Wireless ambulatory ECG

New Research Presented at American Heart Association’s 2023 Scientific Sessions Demonstrates Performance of Continuous Monitoring ECG Data for Improved Prediction of Heart Failure Hospitalization

Retrieved on: 
Monday, November 13, 2023
Medicine, ECG, Disease, Couplet, Research, PVC, SAN, Cardiology, MHS, AHA, Cardiac electrophysiology, Arrhythmia, Mortality, Patient, CHA2DS2–VASc score, Heart failure, IRTC, MAS, Partnership, Medicare, Quality of life, Hospital, American Heart, Wireless ambulatory ECG, Pharmaceutical industry, Medical imaging, Atrial fibrillation, MD

This data was presented at the American Heart Association’s (AHA) 2023 Scientific Sessions in Philadelphia held November 11-13.

Key Points: 
  • This data was presented at the American Heart Association’s (AHA) 2023 Scientific Sessions in Philadelphia held November 11-13.
  • The ambulatory ECG findings with the greatest predictive value were the presence of premature ventricular couplets and presence of Afib.
  • “By incorporating ambulatory ECG data from long-term continuous monitoring, risk prediction of cardiovascular events improves.
  • Clinical data from Centers for Medicare and Medicaid Services were linked with continuous ambulatory ECG data from iRhythm in order to develop a predictive model for heart failure hospitalization.

Nantworks AirStrip® and GE HealthCare Announce Agreement to Commercialize Integrated Patient Monitoring and Cardiac Data Visualization for Healthcare Systems

Retrieved on: 
Monday, December 4, 2023
Software, Managed Care, Professional Services, Telemedicine, Virtual Medicine, Apps, Applications, Technology, Hospitals, Artificial Intelligence, Health Technology, Data Analytics, Cardiology, Health, ECG, Pressure, STEMI, NantWorks, Patient, Multimedia, Creative, Communication, Environment, Health care, Aerodrome, AI, Cardiac output, Data, Vital signs, GE HealthCare, Wireless ambulatory ECG, Pharmaceutical industry, Medical imaging

GE HealthCare is now the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S., offering data visualization technology that healthcare systems can purchase together.

Key Points: 
  • GE HealthCare is now the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S., offering data visualization technology that healthcare systems can purchase together.
  • The combination of GE HealthCare and AirStrip provides a tightly integrated toolset under one solution set.
  • It brings together the wide range of GE HealthCare’s innovative and accurate ECG, cardiac output, and patient monitoring products with AirStrip’s advanced data visualization and monitoring capabilities - all available to clinical care teams on mobile devices and the web.
  • “We are proud to be the exclusive distributor of AirStrip’s innovative cardiac and monitoring technology,” said Catherine Estrampes, President and CEO, U.S. and Canada, GE HealthCare.

IDTechEx Explores Hyper Personalized Approaches to Healthcare

Retrieved on: 
Tuesday, November 28, 2023
ECG, Woman, DSM-IV codes, Research, DNA, Comfort, Gene, Pregnancy, Patient, Science, Heart rate, Genetic testing, Movement, Health, COVID-19, Smartwatch, Parent, Cancer, Diabetes, Cell, Wireless ambulatory ECG, Blood pressure, Nursing, Medical imaging, Medical device, Vaccine, Alivecor

Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.

Key Points: 
  • Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.
  • Oncology is a sector that, for the past twenty years, has utilized this process to make incredible advancements in prescribing personalized medications.
  • With the combination of self-monitoring and DNA sequencing, the future of healthcare industries is becoming more personalized.
  • For the full portfolio of healthcare market research from IDTechEx, please visit www.IDTechEx.com/Research/Healthcare .

IDTechEx Explores Hyper Personalized Approaches to Healthcare

Retrieved on: 
Tuesday, November 28, 2023
ECG, Woman, DSM-IV codes, Research, DNA, Comfort, Gene, Pregnancy, Patient, Science, Heart rate, Genetic testing, Movement, Health, COVID-19, Smartwatch, Parent, Cancer, Diabetes, Cell, Wireless ambulatory ECG, Blood pressure, Nursing, Medical imaging, Medical device, Vaccine, Alivecor

Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.

Key Points: 
  • Tracking information within the body and having doctors able to prescribe personalized cancer treatments demonstrate how technologies are creating a new future of healthcare.
  • Oncology is a sector that, for the past twenty years, has utilized this process to make incredible advancements in prescribing personalized medications.
  • With the combination of self-monitoring and DNA sequencing, the future of healthcare industries is becoming more personalized.
  • For the full portfolio of healthcare market research from IDTechEx, please visit www.IDTechEx.com/Research/Healthcare .

AccurKardia Delivers Its ECG Interpretation Software Within the Lucem Health Reveal Family of Clinical AI Solutions

Retrieved on: 
Thursday, November 9, 2023
Cardiology, Software, General Health, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, ECG, Wireless ambulatory ECG, Conditional sentence, Risk, Partnership, Arrhythmia, Patient, Diagnosis, Medical device

AccurKardia , an ECG-led diagnostics software company, today announced a multi-year agreement with Lucem Health , a leading provider of clinical AI solutions.

Key Points: 
  • AccurKardia , an ECG-led diagnostics software company, today announced a multi-year agreement with Lucem Health , a leading provider of clinical AI solutions.
  • The partnership paves the way for AccurKardia to integrate its FDA-Cleared ECG Interpretation Software Platform, AccurECG™ Analysis System (“AccurECG”), into Lucem Health Reveal, a family of solutions that identify patients who may be at higher risk of severe or chronic diseases.
  • AccurKardia’s AccurECG is a cloud-based, device-agnostic, fully automated ECG interpretation software platform that can detect up to 13 arrhythmias.
  • This partnership with Lucem Health allows us to bring the power of our technology to Lucem Health’s clinical AI solution,” said Juan C. Jiménez , CEO of AccurKardia.

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

Retrieved on: 
Monday, November 6, 2023
Șaeș, ECHO, Acute myeloid leukemia, Physical examination, Aes, Food, Progression-free survival, ECOG, Wireless ambulatory ECG, Treatment, MD, Eastern Cooperative Oncology Group, PFS, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, HIV disease progression rates, SD, Washington University School of Medicine, Clinical trial, Cardiotoxicity, STS, RECIST, ANN, Safety, Vital signs, Patient, Toxicity, Pharmaceutical industry

HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company's ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).

Key Points: 
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
  • We look forward to further data readouts from this trial and understanding the full potential of Annamycin for the treatment of STS lung mets."
  • The other subject maintained SD through 8 cycles prior to progressing ~6.9 months after initiating treatment with Annamycin.
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

Retrieved on: 
Saturday, October 21, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, FDA, Heart, NSCLC, Food, Wireless ambulatory ECG, Cardiomyopathy, Breakthrough therapy, LVEF, PFS, Conference, CNS, Periodic breathing, International Association, Fever, Priority review, Cough, Lung, QT, QT interval, ILD, Lung cancer, Patient, Electrolyte, Criticism of the Food and Drug Administration, Pharmaceutical industry

In August 2023, TAGRISSO with the addition of chemotherapy also received Breakthrough Therapy Designation from the FDA in this setting.

Key Points: 
  • In August 2023, TAGRISSO with the addition of chemotherapy also received Breakthrough Therapy Designation from the FDA in this setting.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.7% of the 1479 TAGRISSO-treated patients; 0.3% of cases were fatal.
  • Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.
  • For symptomatic congestive heart failure, permanently discontinue TAGRISSO
    Keratitis was reported in 0.7% of 1479 patients treated with TAGRISSO in clinical trials.

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023
DSM-IV codes, MWT, Wireless ambulatory ECG, Congress, Pathology, Dizziness, Idiopathic hypersomnia, Maintenance, Alkermes, Pharmacokinetics, Sleep, Urination, OX2R, Dysfunction, Disease, NT1, Biology, Wakefulness, Sleep onset latency, Safety, Vital signs, ALKS, Patient, Insomnia, Pharmaceutical industry, Narcolepsy

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023
DSM-IV codes, MWT, Wireless ambulatory ECG, Congress, Pathology, Dizziness, Idiopathic hypersomnia, Maintenance, Alkermes, Pharmacokinetics, Sleep, Urination, OX2R, Dysfunction, Disease, NT1, Biology, Wakefulness, Sleep onset latency, Safety, Vital signs, ALKS, Patient, Insomnia, Pharmaceutical industry, Narcolepsy

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.